Edwards Lifesciences is a leading American medical technology company focused on structural heart disease and cardiovascular care. The company is particularly well known for developing artificial heart valves, transcatheter valve-replacement technologies and minimally invasive therapies for patients with heart-valve disease.

Unlike many diversified medical-device companies, Edwards has increasingly focused its business around structural heart care. Its current technology portfolio includes transcatheter aortic heart valves, mitral and tricuspid therapies, surgical heart valves and implantable heart-failure management technologies.

The company has played an important role in the development of less-invasive heart-valve procedures, especially transcatheter aortic valve replacement (TAVR).

What Does Edwards Lifesciences Make?

Edwards develops and manufactures a specialized range of cardiovascular medical devices, including:

• Transcatheter aortic heart valves
• Surgical aortic valves
• Surgical mitral valves
• Transcatheter mitral valve technologies
• Transcatheter tricuspid valve technologies
• Valve-repair systems
• Annuloplasty rings
• Aortic valved conduits
• Heart-failure monitoring and management technologies
• Delivery systems
• Cardiovascular procedure accessories

Its portfolio is designed around treating structural abnormalities of the heart, particularly diseased heart valves.

Understanding Heart Valve Disease

The human heart contains four major valves:

1. Aortic valve
2. Mitral valve
3. Tricuspid valve
4. Pulmonary valve

These valves help control the direction of blood flow through the heart.

When a valve becomes narrowed, it can cause stenosis. When it does not close properly and blood leaks backward, the condition can involve regurgitation.

Depending on the severity and type of disease, treatment may include medication for symptom management, valve repair, surgical valve replacement or transcatheter valve replacement.

Edwards develops technologies for several of these treatment pathways.

Transcatheter Aortic Valve Replacement

One of Edwards Lifesciences’ most important technologies is TAVR, or transcatheter aortic valve replacement.

TAVR provides a less-invasive approach to replacing a diseased aortic valve compared with conventional open-heart surgical valve replacement in appropriate patients.

Instead of opening the chest in the same way as traditional surgical replacement, a replacement valve is delivered through a catheter and positioned within the diseased aortic valve.

The Edwards SAPIEN family has been central to the company’s TAVR business.

SAPIEN Transcatheter Heart Valves

The SAPIEN platform is one of the most recognized Edwards technologies.

The current transcatheter aortic portfolio includes:

• SAPIEN 3
• SAPIEN 3 Ultra
• SAPIEN 3 Ultra RESILIA

Edwards’ official portfolio identifies SAPIEN 3 Ultra RESILIA and SAPIEN 3 Ultra as transcatheter aortic valve technologies.

SAPIEN 3 Ultra RESILIA

SAPIEN 3 Ultra RESILIA combines Edwards’ transcatheter valve platform with its RESILIA tissue technology.

The technology is intended for appropriately selected patients requiring transcatheter aortic valve replacement.

Edwards reported that its SAPIEN 3 Ultra RESILIA platform remained a major part of its TAVR business in the United States.

How TAVR Works

During TAVR, a compressed replacement valve is mounted on a delivery system.

The catheter is advanced to the heart through an appropriate access route. Once positioned inside the diseased aortic valve, the replacement valve is expanded and positioned to take over the valve’s function.

The exact access route and procedure depend on the patient’s anatomy, medical condition and clinical judgment.

TAVR is performed by specialized heart teams that can include interventional cardiologists, cardiac surgeons, imaging specialists, anesthesiology professionals and other healthcare staff.

Surgical Heart Valves

Edwards also manufactures conventional surgical heart valves.

These valves are implanted during surgical valve replacement procedures.

Its surgical portfolio includes:

• Aortic valves
• Mitral valves
• Aortic valved conduits
• Rapid-deployment valves
• Annuloplasty rings

Edwards currently lists INSPIRIS RESILIA, MITRIS RESILIA, KONECT RESILIA and the EDWARDS INTUITY Elite valve system among its surgical structural-heart products.

INSPIRIS RESILIA Aortic Valve

The INSPIRIS RESILIA aortic valve is one of Edwards’ major surgical tissue-valve products.

It uses RESILIA tissue technology and is designed for surgical aortic valve replacement.

The valve is part of Edwards’ current RESILIA tissue portfolio.

RESILIA Tissue Technology

One of Edwards’ important areas of valve research is RESILIA tissue technology.

Bioprosthetic heart valves use biological tissue. One challenge with tissue valves is structural valve deterioration, including changes associated with calcium buildup.

Edwards describes RESILIA as incorporating its Integrity Preservation technology, designed to address mechanisms associated with calcification of the tissue.

Clinical studies and long-term follow-up are important when evaluating the durability and performance of tissue valves. Edwards maintains ongoing clinical research around its RESILIA portfolio.

MITRIS RESILIA Mitral Valve

The MITRIS RESILIA mitral valve is designed for surgical replacement of the mitral valve.

The mitral valve is located between the left atrium and left ventricle and plays an important role in controlling blood flow through the left side of the heart.

Edwards specifically describes MITRIS RESILIA as a surgical mitral valve designed for the pressures and requirements of the mitral position.

KONECT RESILIA Aortic Valved Conduit

Another product in the surgical portfolio is the KONECT RESILIA aortic valved conduit.

A valved conduit combines a valve with a vascular graft and can be used during selected complex aortic surgical procedures.

It is intended for specialized cardiovascular surgery rather than routine valve replacement.

EDWARDS INTUITY Elite Valve System

The EDWARDS INTUITY Elite valve system is a rapid-deployment surgical valve system.

Rapid-deployment technology is designed to facilitate implantation during appropriate surgical aortic valve replacement procedures.

The system forms part of Edwards’ surgical aortic valve portfolio alongside conventional tissue-valve technologies.

Mitral Valve Repair and Replacement

The mitral valve is another major focus for Edwards.

The company has developed both surgical and transcatheter technologies for mitral disease.

Its transcatheter mitral portfolio includes:

• PASCAL Precision
• SAPIEN M3

The PASCAL Precision system is a transcatheter valve-repair technology, while SAPIEN M3 is a transcatheter mitral valve-replacement system.

PASCAL Precision Transcatheter Valve Repair System

The PASCAL Precision system is designed for transcatheter treatment of selected mitral and tricuspid valve conditions.

It provides a catheter-based approach to valve repair, potentially allowing treatment without conventional open-heart surgery in appropriately selected patients.

The technology belongs to Edwards’ transcatheter mitral and tricuspid therapy portfolio.

SAPIEN M3 Transcatheter Mitral Valve Replacement

Edwards is also developing transcatheter mitral valve replacement technology.

The SAPIEN M3 system is designed as a transcatheter mitral valve replacement platform.

This technology is particularly relevant because mitral valve replacement through a catheter presents different anatomical and technical challenges compared with aortic valve replacement.

Tricuspid Valve Technology

The tricuspid valve is located between the right atrium and right ventricle.

Historically, treatment options for severe tricuspid disease have been more limited than those for aortic disease. Edwards has therefore invested heavily in developing transcatheter tricuspid technologies.

Its current portfolio includes the EVOQUE Tricuspid Valve Replacement System.

EVOQUE Tricuspid Valve Replacement System

The EVOQUE system is a transcatheter tricuspid valve replacement technology.

It is designed to provide a less-invasive treatment option for appropriately selected patients with significant tricuspid valve disease.

Edwards lists EVOQUE within its dedicated transcatheter tricuspid technology portfolio.

Annuloplasty Rings

Edwards also manufactures valve-repair products such as mitral and tricuspid annuloplasty rings.

The annulus is the ring-like structure surrounding a heart valve.

During valve repair, an annuloplasty ring can be used to reshape or reinforce the valve annulus, helping restore appropriate valve function.

These products are generally used during surgical valve-repair procedures.

Structural Heart Technology

The term structural heart covers diseases involving the heart’s valves and other anatomical structures.

Edwards’ current structural-heart portfolio includes:

• Aortic valve replacement
• Mitral valve repair
• Mitral valve replacement
• Tricuspid valve replacement
• Surgical valve replacement
• Valve repair
• Heart-failure management

The company describes itself as a structural-heart innovation company, with technologies designed around complex cardiovascular conditions.

Implantable Heart-Failure Management

Edwards has also expanded into technologies for heart-failure management.

Its current corporate portfolio identifies implantable heart-failure management as one of its four major technology areas alongside transcatheter heart valves, mitral/tricuspid technologies and surgical valve technologies.

These technologies are intended to provide physicians with additional information or therapeutic options for selected patients with heart failure.

Edwards’ Cardiovascular Research

Research and clinical evidence are particularly important for heart-valve technology.

Valve manufacturers need to demonstrate safety, durability and performance through laboratory testing, clinical studies and long-term follow-up.

Edwards maintains clinical programs examining the performance of its valve technologies, including long-term studies of RESILIA tissue.

The company’s research areas include:

• Valve durability
• Transcatheter valve design
• Valve repair
• Valve replacement
• Delivery systems
• Imaging
• Patient selection
• Heart-failure management
• Minimally invasive cardiovascular procedures

Edwards’ 2025 Business Performance

Edwards reported $6.07 billion in 2025 sales from continuing operations, representing 11.5% reported growth compared with 2024.

Its 2025 product-group sales included approximately:

• $4.49 billion from Transcatheter Aortic Valve Replacement
• $550.6 million from Transcatheter Mitral and Tricuspid Therapies
• $1.03 billion from Surgical Structural Heart

The company reported particularly strong growth in its mitral and tricuspid business, which grew more than 50% on a reported basis in 2025.

These numbers demonstrate how important TAVR remains while newer mitral and tricuspid technologies are becoming significant growth areas.

Edwards and Minimally Invasive Cardiac Care

One of the major trends in cardiovascular medicine is the development of less-invasive approaches to treating structural heart disease.

Traditional valve replacement can require open-heart surgery. Transcatheter procedures can provide an alternative for selected patients.

Edwards’ technologies are designed around this transition, particularly in:

• TAVR
• Transcatheter mitral repair
• Transcatheter mitral replacement
• Transcatheter tricuspid replacement

However, less-invasive does not mean risk-free. Patient selection and treatment decisions must be made by an appropriately trained heart team.

Edwards Lifesciences in India

Edwards Lifesciences has an established presence in India.

The company lists Edwards Lifesciences (India) Pvt. Ltd. with its regional headquarters in Mumbai. Its Indian operation provides support for hospitals and healthcare professionals.

Edwards technologies in India are associated with structural-heart treatment areas including:

• Aortic valve replacement
• TAVR
• Surgical heart valves
• Mitral valve therapies
• Tricuspid valve therapies

The availability of a particular device depends on Indian regulatory approvals, hospital capabilities, physician training and product availability.

Heart Valve Treatment and Edwards Technology

Edwards’ technologies can be broadly matched to different treatment approaches: Heart problem Possible Edwards technology Aortic stenosis SAPIEN transcatheter valves Surgical aortic valve replacement INSPIRIS RESILIA and other surgical valves Mitral valve disease PASCAL, MITRIS RESILIA, SAPIEN M3 Tricuspid disease EVOQUE and PASCAL technologies Complex aortic surgery KONECT RESILIA Surgical valve repair Annuloplasty rings Selected heart-failure patients Implantable heart-failure management technology

This table is a general overview, not a recommendation for any individual patient.

Why Edwards Lifesciences Is Important

Edwards is important because it has specialized heavily in structural heart disease rather than maintaining a very broad medical-device portfolio.

Its major strengths include:

1. TAVR
2. Surgical heart valves
3. Tissue-valve technology
4. Mitral valve repair
5. Mitral valve replacement
6. Tricuspid valve replacement
7. Annuloplasty
8. Heart-failure management
9. Minimally invasive cardiac treatment
10. Long-term valve research

The company’s technology portfolio is therefore closely connected to one of the most important areas of modern cardiovascular medicine.

Important Corporate Change: Critical Care Business

An important point for current articles is that Edwards Lifesciences’ former Critical Care business is no longer part of Edwards.

Edwards’ current website states that Edwards Lifesciences Critical Care is now part of BD (Becton, Dickinson and Company).

Therefore, older articles that list Edwards’ hemodynamic monitoring and critical-care equipment as current Edwards products may be outdated.

The company’s current strategic focus is much more concentrated on structural heart technologies.

Frequently Asked Questions

What is Edwards Lifesciences?

Edwards Lifesciences is a U.S.-based medical technology company specializing in structural heart disease, heart valves, transcatheter valve therapies and related cardiovascular technologies.

What does Edwards Lifesciences manufacture?

The company develops transcatheter and surgical heart valves, valve-repair systems, mitral and tricuspid therapies, aortic valved conduits, annuloplasty rings and implantable heart-failure management technologies.

Is Edwards Lifesciences a heart valve company?

Yes. Heart-valve technology is one of the company’s central areas of specialization, particularly aortic, mitral and tricuspid valve therapies.

What is TAVR?

TAVR stands for Transcatheter Aortic Valve Replacement. It is a catheter-based method of replacing a diseased aortic valve in appropriately selected patients.

What is the SAPIEN valve?

SAPIEN is Edwards Lifesciences’ family of transcatheter heart valves, particularly associated with TAVR. The current portfolio includes SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA.

What is INSPIRIS RESILIA?

INSPIRIS RESILIA is a surgical aortic tissue valve incorporating Edwards’ RESILIA tissue technology.

What is MITRIS RESILIA?

MITRIS RESILIA is a surgical mitral tissue valve designed for mitral valve replacement.

What is EVOQUE?

EVOQUE is Edwards’ transcatheter tricuspid valve replacement system.

What is PASCAL?

PASCAL Precision is a transcatheter valve-repair system used in selected mitral and tricuspid valve conditions.

Does Edwards Lifesciences operate in India?

Yes. Edwards has an India operation headquartered in Mumbai and supports healthcare professionals and hospitals in the Indian market.

Does Edwards still make critical-care equipment?

Edwards’ former Critical Care business is now part of BD. Therefore, current Edwards should primarily be described as a structural-heart company rather than as a broad critical-care equipment manufacturer.

Conclusion

Edwards Lifesciences has become one of the world’s most important companies in structural heart technology.

Its best-known contribution is the development of transcatheter aortic valve replacement technology through the SAPIEN family. However, its current portfolio extends much further, covering surgical tissue valves, mitral valve repair and replacement, tricuspid valve replacement and implantable heart-failure management.

Products such as SAPIEN 3 Ultra RESILIA, INSPIRIS RESILIA, MITRIS RESILIA, PASCAL Precision and EVOQUE represent different approaches to treating complex heart-valve conditions.

With continued investment in minimally invasive procedures, valve durability, transcatheter technology and clinical research, Edwards Lifesciences remains a major force in the evolution of modern cardiac care.